Abstract:Abstract Poster session 1, September 21, 2022, 12:30 PM - 1:30 PM Objectives The opportunistic fungal infections represent an increasing threat to humans with the increase of immunocompromised patients, in which Candida albicans is the most common fungal pathogen. Though fluconazole (FCA) is still the first line choice to treat C. albicans infections, several limitations such as an increase in drug resistance compromised its clinical application. This study proposes a combination therapy of deferoxamine (DFO) and FCA to overcome C. albicans resistance. Methods Checkerboard microdilution assay was used to determine the minimum inhibitory concentration (MIC) of DFO used alone and in combination with FCA against FCA-resistant Candida Spp. Spot assay and time-kill curves were used to investigate the cell viability and dynamic inhibitory effect. Hyphal formation was performed to investigate the underlying mechanism of DFO. Then, a murine model of cutaneous candidiasis was established to explore the in vivo synergistic activity of DFO and FCA. Results DFO combined with FCA showed synergistic antifungal activity against FCA-resistant C. albicans, with a fractional inhibitory concentration index (FICI) of 0.25. Moreover, DFO combined with FCA significantly inhibited the activity of C. glabrata cells, which is naturally insensitive to antifungal drugs. The spot assay and time-kill curve assay indicated that DFO can turn the fungistasis activity of FCA into fungicidal activity. Hyphal formation study showed the inhibition of hyphal induction of C. albicans. DFO combined with FCA also significantly inhibited the expression of Cek1 MAPK signaling pathway-related genes (CEK1 and CPH1) and adhesion-related genes (ALS1). In vivo data showed DFO combined with FCA significantly reduced the pustule, CFU numbers, and inflammatory cell infiltration of skin tissue. Conclusion Our results suggest that DFO combined with FCA inhibited the transformation of yeast-hyphae through Cek1 MAPK signaling pathway, resulting in reduced infectivity and resistance of C. albicans in vitro and in vivo, which may provide a new option for the treatment of cutaneous candidiasis.

Potent in Vitro Synergism of Fluconazole and Osthole Against Fluconazole-Resistant Candida Albicans.

Antifungal Activity of Osthol in Vitro and Enhancement in Vivo Through Eudragit S100 Nanocarriers

Synergistic in Vitro Activity of Sodium Houttuyfonate with Fluconazole Against Clinical Candida Albicans Strains under Planktonic Growing Conditions

Potent in Vitro Synergism of Fluconazole and Berberine Chloride Against Clinical Isolates of Candida Albicans Resistant to Fluconazole

Synergistic Effect of the Combination of Deferoxamine and Fluconazole in Vitro and in Vivo Against Fluconazole-Resistant Candida Spp.

Synergistic Antifungal Effect of Fluconazole Combined with Licofelone Against Resistant Candida Albicans

In Vitro Synergism of Fluconazole and Baicalein Against Clinical Isolates of Candida Albicans Resistant to Fluconazole.

Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation.

The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans

The Combination of Minocycline and Fluconazole Causes Synergistic Growth Inhibition Against Candida Albicans: an in Vitro Interaction of Antifungal and Antibacterial Agents.

Synergistic and drug-resistant reversing effects of diorcinol D combined with fluconazole against Candida albicans.

Small Molecule II-6s Synergises with Fluconazole Against Candida Albicans.

Synergistic Antifungal Effects of Curcumin Derivatives As Fungal Biofilm Inhibitors with Fluconazole.

Antifungal Activity of Minocycline and Azoles Against Fluconazole-Resistant Candida Species

Synthesis and Synergistic Antifungal Effects of Monoketone Derivatives of Curcumin Against Fluconazole-Resistant Candida Spp.

Synergic effect of deferoxamine combined with fluconazole against fluconazole-resistant <i>Candida</i> Spp. through inhibited Cek1 MAPK signaling pathway

Combination of fluconazole with natural compounds: A promising strategy to manage resistant Candida albicans infections

Synergistic effect of mangiferin in combination with fluconazole against fluconazole-resistant Candida albicans

Synergistic Activity of Azoles with Amiodarone Against Clinically Resistant Candida Albicans Tested by Chequerboard and Time-Kill Methods.

Fluconazole Inhibits Cellular Ergosterol Synthesis to Confer Synergism with Berberine Against Yeast Cells.

Ambroxol Hydrochloride Combined with Fluconazole Reverses the Resistance of Candida albicans to Fluconazole